

Clinical Oversight Review Board (CORB) Criteria for Prescribing Enfortumab vedotin-ejfv (Padcev)

Non-Formulary **enfortumab vedotin-ejfv (Padcev)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-formulary **enfortumab vedotin-ejfv (Padcev)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by an oncologist or hematologist
- Patient is at least 18 years of age
- Diagnosis of locally advanced or metastatic urothelial carcinoma
- Prior treatment with platinum-based therapy in the locally advanced/metastatic setting
- Prior treatment with an immune checkpoint inhibitor in the locally advanced/metastatic setting